• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Helix Acquisition Corp. II

    7/30/25 4:15:57 PM ET
    $HLXB
    Get the next $HLXB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Helix Acquisition Corp. II

    (Name of Issuer)


    Class A Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)


    G4444H101

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G4444H101


    1Names of Reporting Persons

    Integrated Core Strategies (US) LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    833,125.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    833,125.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    833,125.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G4444H101


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    897,251.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    897,251.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    897,251.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G4444H101


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    897,251.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    897,251.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    897,251.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G4444H101


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    897,251.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    897,251.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    897,251.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Helix Acquisition Corp. II
    (b)Address of issuer's principal executive offices:

    Cormorant Asset Management, LP, 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116
    Item 2. 
    (a)Name of person filing:

    Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Class A Ordinary Shares, par value $0.0001 per share
    (e)CUSIP No.:

    G4444H101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Integrated Core Strategies (US) LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:07/29/2025
     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:07/29/2025
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:07/29/2025
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:07/29/2025

    Comments accompanying signature:  ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of July 29, 2025, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $HLXB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLXB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HLXB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Tipirneni Praveen P.

    3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    8/18/25 5:20:19 PM ET
    $HLXB

    SEC Form 3 filed by new insider Doig Michelle

    3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    8/18/25 5:19:10 PM ET
    $HLXB

    SEC Form 3 filed by new insider Mccormick Frank

    3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    8/18/25 5:17:41 PM ET
    $HLXB

    $HLXB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Helix Acquisition Corp. II

    SCHEDULE 13G - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)

    8/18/25 5:59:19 PM ET
    $HLXB

    Amendment: SEC Form SCHEDULE 13D/A filed by Helix Acquisition Corp. II

    SCHEDULE 13D/A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)

    8/13/25 8:29:42 AM ET
    $HLXB

    Helix Acquisition Corp. II filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Changes in Control of Registrant, Leadership Update, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD

    8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

    8/12/25 8:54:37 PM ET
    $HLXB

    $HLXB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

    Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million private investment in public equity ("PIPE"), led by Cormorant Combining approximately $120 million from the former Helix II trust account (reflecting a final redemption rate of approximately 39% which is the second lowest redemption rate for a biotech de-SPAC transaction since 2022) with the PIPE provides approximately $382 million in gross proceeds Net proceeds will be used to accelerate the development of BBOT's pipeline of clinical-stage RAS-targeted oncology drug candidat

    8/11/25 4:30:00 PM ET
    $HLXB

    Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

    Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing2nd lowest redemption rate for a biotech de-SPAC transaction since 2022 BOSTON & SOUTH SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that Hel

    8/6/25 7:33:00 AM ET
    $BBIO
    $HLXB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

    Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company ("SPAC") sponsored by Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that the registration statement on Form S-4 (File No. 333-288222) (as amended, the "Registration Statement"), filed by Helix and BBOT, relating to the previously-announced b

    7/11/25 7:43:00 AM ET
    $BBIO
    $HLXB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HLXB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Helix Acquisition Corp. II

    SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

    11/14/24 1:22:40 PM ET
    $HLXB

    SEC Form SC 13G filed by Helix Acquisition Corp. II

    SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

    2/23/24 4:30:20 PM ET
    $HLXB

    SEC Form SC 13G filed by Helix Acquisition Corp. II

    SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

    2/23/24 4:01:43 PM ET
    $HLXB